
COGT Stock Forecast & Price Target
COGT Analyst Ratings
Bulls say
Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases. With a promising pipeline of targeted oncology treatments, including the potential launch of its flagship drug bezuclastinib for multiple indications, the company is well-positioned in the market. Despite potential risks such as clinical trial setbacks and competition, Cogent's strong financials, with a projected cash runway into 2028, make it a compelling investment opportunity.
Bears say
Cogent Biosciences is facing hurdles in obtaining regulatory approvals for its precision therapies due to potential negative clinical data, slower development timelines, and setbacks in later-stage trials. Additionally, there is a risk of failure to obtain regulatory approvals and setbacks with its earlier-stage candidates, which could hinder the company's commercial success and lead to long-term dilution risk for investors. As a result, there is a negative outlook on the company's stock.
This aggregate rating is based on analysts' research of Cogent Biosciences, Inc. and is not a guaranteed prediction by Public.com or investment advice.
COGT Analyst Forecast & Price Prediction
Start investing in COGT
Order type
Buy in
Order amount
Est. shares
0 shares